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A B S T R A C T
Apart from the numerous physiological functions of MDR1, it is widely known for its role in granting multidrug
resistance to cancer cells. This ATP-driven transmembrane protein exports a wide range of chemotherapeutic
agents from cancer cells, thereby deterring drugs to reach effective intracellular concentrations. Thus, inhibition
of MDR1 expression or function would be a viable option to enhance the accumulation of cytotoxic agents in
cancer cells which in turn could improve significantly the success rate of chemotherapy. Although, several
pharmacological inhibitors have been designed and tested in the past, due to their unsuccessful translation to
clinical application, there is still ongoing research to find suitable compounds to manipulate MDR1 function and
potentially overturn multidrug resistance.
In the present study, we demonstrate that novel DHT-derived A-ring-fused arylpyrimidinone derivatives,
based on their acetylation status, can inhibit MDR1 efflux activity in MDR1 overexpressing multidrug-resistant
breast adenocarcinoma cells. Strikingly, all derivatives carrying an acetoxy group on the sterane D-ring were
highly potent in hindering Rhodamine 123 export via MDR1, however deacetylated molecules were not capable
to exert a similar effect on multidrug resistant cancer cells. The possible molecular and cellular mechanisms
underlying the efflux pump inhibiting function of acetylated derivatives were dissected using the most potent
MDR1 inhibitor, compound 10g and its deacetylated counterpart (11g). Importantly, molecule 10g was able to
sensitize drug resistant cells to doxorubicin-induced apoptosis, further verifying the highly advantageous nature
of efflux pump inhibition upon chemotherapy. Our experiments also revealed that neither mitochondrial da-
mage, nor MDR1 gene regulation could lay behind the MDR1 inhibitory function of compound 10g. Molecular
docking studies were carried out to analyze the interactions of 10g and 11g with MDR1, however no significant
differences in their binding properties were observed. Nevertheless, our results indicate that the ER stress in-
ducing potential of molecule 10g might be the fundamental mechanism behind its inhibitory action on MDR1.
With additional studies, our work can yield a structural platform for a new generation of small molecule MDR1
inhibitors to sensitize drug resistant cancer cells and at the same time it elucidates the exemplary involvement of
endoplasmic reticulum stress in the molecular events to defeat multidrug resistance.
1. Introduction
Although a considerable amount of scientific effort has been dedi-
cated to understand the cellular and molecular events that drive cancer
recurrence, invasion and metastasis, and important advancements have
been achieved in identifying potential pharmacological targets,
nevertheless, adequately competent therapeutic approaches to defeat
malignant cells are still wanted. The first line treatment for most cancer
types is usually, small molecular drug-based chemotherapy, where the
development of drug resistance is, unfortunately, a likely outcome.
Decreased sensitivity to several cytotoxic drugs and broad cross-re-
sistance to a large number of structurally dissimilar antineoplastic
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agents emerge quickly, advancing the evolution of multidrug-resistant
(MDR) cancer phenotypes. MDR, either intrinsic or acquired, displays a
substantial hurdle to effective cancer therapy leading to poor patient
survival (Luqmani, 2005). Although the cellular and molecular features
of MDR involve modification of signaling pathways, endurance of oxi-
dative stress and increased apoptotic threshold, the major component of
the cancer cells’ strategy to reduce cellular accumulation and thereby
evading the toxic effects of chemotherapy drugs is the overexpression of
various efflux pumps. Such an ATP-dependent transmembrane drug
transporter protein is P-glycoprotein, also known as MDR1 or ABCB1,
which is encoded by the multidrug resistance gene 1 (MDR1). Via such
ABC transporters - membrane-residing pumps containing ATP binding
motives - cytotoxic agents can be readily expelled from the cytoplasm
immediately after their uptake, at almost the same speed as they en-
tered tumor cells, leaving no time to exert their anticancer activities
(Gillet and Gottesman, 2010; Szakács et al., 2014, 2004). As a con-
sequence, a broad spectrum of approaches was tested to suppress the
expression and the function of ABC transporters, in particular, those of
MDR1, in order to potentially overturn MDR (Callaghan et al., 2014;
Chen and Tiwari, 2011; Choi and Yu, 2014). Along this line, based on
the protein structure and on the conformational changes associated
with MDR1 efflux activity, a multitude of inhibitors have been designed
and developed to hinder drug transport across MDR1; sadly, translation
of their application to the clinical practice have failed owing to side-
effects related to their pharmacological properties (i.e. cardiotoxicity
elicited by verapamil treatment) (Coley, 2010; Ekins et al., 2002;
Kathawala et al., 2015; Robert and Jarry, 2003). Despite the somewhat
disappointing results of the clinical trials performed with some of the
selected MDR1 inhibitors, there is still intensive ongoing research to
find the ultimate compound/s with the unique capability to manipulate
specifically MDR1 activity without exerting unpredictable toxicities,
thereby opening avenues to overcome MDR cancer.
Among the numerous candidates designed for MDR1 inhibition,
several natural and synthetic steroids have already been examined
(De Ravel et al., 2015). In synthetic studies, physiologically relevant
steroids have been utilized as precursors, where structure optimization
was aimed to establish or enhance the inhibiting performance of the
molecule/s on MDR1 without triggering undesired interactions. Mod-
ulation of the substitution profile of natural sex-hormones, glucocorti-
coids or other steroids enables a huge versatility of chemical mod-
ifications leading to a substantial transformation of the
physicochemical, biological and pharmacokinetic properties of the
parent compound. In fact, progesterone and its synthetic derivatives
have been thoroughly screened and it was found that the fairly weak
activity of progesterone on MDR1 could be enhanced by introducing
7α-thiophenyl groups, 11α-benzoate, and carbamate substituents or via
modifications at the 17β-acetyl side chain (Ichikawa-Haraguchi et al.,
1993; Leonessa et al., 2002). MDR1 inhibiting properties were observed
also for steroidal anti-estrogens, for some synthetic glucocorticoid de-
rivatives, as well as for modified primary and secondary conjugated and
unconjugated bile acids (Cooray et al., 2006; Lo et al., 2008;
Rocheblave et al., 2016). Based on structure−activity studies, mod-
eling and docking investigations and fluorescence-based techniques, it
seems plausible that interactions between MDR1 and its steroid mod-
ulators are centered near the ATP-binding domain of the transporter,
suggesting that the influence on efflux activity exhibited by these
compounds is associated with the ATP-driven conformational change
required for drug transport (Dayan et al., 1997; Li et al., 2005; Mares-
Samano et al., 2009a).
Modifications of natural steroids by heterocycles either connected to
or condensed with one of the steroid rings have gathered grounds in
recent developments. Among various modifications, the introduction of
pyrimidines is exceptionally relevant as the resultant hybrid derivatives
with high stability, tunable composition and multifunctionality, man-
ifest an extensive range of biological properties, such as antiviral, an-
timicrobial, antioxidant, as well as anti-cancer activities (Gore and
Rajput, 2013; Kaur et al., 2014; Mohana Roopan and Sompalle, 2016).
In view of the biological relevance of steroidal heterocycles, novel ar-
ylpyrimidine-fused androstanes were recently synthesized via three-
component, modified Biginelli-type reactions under microwave irra-
diation and the cytotoxicity of the compounds was screened in vitro on
two prostate cancer (PC-3 and DU 145), on MCF-7 breast cancer and on
non-cancerous lung fibroblast (MRC-5) cell lines (Baji et al., 2017).
Remarkable association between structure and biological activity were
noted since acetylated, A-ring-fused 4′-arylpyrimidin-2′-one derivatives
of dihydrotestosterone (DHT) 17-acetate exhibited significant cyto-
toxicity, whereas deacetylated analogs failed to induce cancer cell
death. We concluded that arylpyrimidines can be utilized in future drug
design and synthetic approaches as structural scaffolds of androstanes,
motivating the rational design and pharmacological investigation of
additional derivatives and the highly advantageous cytotoxic features
of acetylated androstanes with the arylpyrimidine modifications could
be further exploited to kill different types of cancer cells.
Thus, our next aim was to test the remarkable anticancer perfor-
mance of acetylated DHT- arylpyrimidinone derivatives on cancer cells
with multidrug-resistant phenotype and to examine the impact of these
compounds on the efflux activity and on the cellular responses of MDR
cancer cells. Therefore, the present study was undertaken with the aim
to examine the MDR1 inhibiting properties of a series of semi-synthetic,
acetylated as well as deacetylated A-ring-modified heterocyclic DHT
derivatives - selected from the compound library synthesized and in-
vestigated previously (Baji et al., 2017) - in order to reveal struc-
ture−activity criteria relevant for attenuating drug efflux via MDR1.
Since we could identify several compounds exhibiting prominent MDR1
inhibiting capacity, using one suitable compound the mechanism be-
hind its action on multidrug-resistant breast cancer cells has been in-
vestigated in details. Since attenuation of MDR1 activity by the syn-
thetized androstane derivatives can be the result of transcriptional and
translational suppression of MDR1, or of mitochondrial dysfunction
leading to decreased ATP generation, apoptosis or endoplasmic re-
ticulum stress, we tested these cellular and molecular events in multi-
drug-resistant MCF-7/KCR cells, following treatments with the most
promising DHT derivative.
2. Materials and methods
2.1. Synthesis of androstano-pyrimidinones
The synthesis of arylpyrimidinone-modified DHT derivatives was
reported previously (Baji et al., 2017). Briefly, DHT-acetate (1 mmol),
para-substituted benzaldehyde (2 mmol) and urea (1 mmol) were dis-
solved in acetic acid (10 mL) and concentrated H2SO4 (2 drops) was
added. The mixture was irradiated in a closed vessel at 110 °C for
10 min using a CEM Corporation Focused Microwave System, Model
Discover SP. After completion of the reaction, the mixture was poured
into saturated NaHCO3 solution (10 mL) and extracted with di-
chloromethane (2 × 10 mL). The combined organic layers were washed
with water (10 mL), dried over anhydrous Na2SO4 and evaporated in
vacuo. The residue was then dissolved in acetone (20 mL) and 1 mL
Jones reagent (1.8 M) was added. The mixture was poured into water
after 30 min of stirring at room temperature, and extracted with di-
chloromethane (2 × 10 mL). The combined organic layers were dried
over anhydrous Na2SO4 and evaporated in vacuo. The crude product
was purified by column chromatography using MeOH/CH2Cl2 = 5:95
as eluent to give 10b−g (Yields: 60−69%). For deacetylation, com-
pound 10b–g (0.25 mmol) was dissolved in methanol (10 mL), and
KOH (1 mmol) was added. The solution was stirred at room tempera-
ture for 8 h, and then diluted with water. After adding NH4Cl, the
mixture was cooled and the resulting precipitate was filtered off, wa-
shed with water and dried to give 11b−g (Yield: 85−95%). The ori-
ginal compound numbers used in Baji et al. (Baji et al., 2017) were
retained in this manuscript for clarity and comparability.
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2.2. Cell culture
The MCF-7 human breast adenocarcinoma cell line was obtained
from ATCC. The drug-resistant MCF-7/KCR cell line was developed
from MCF-7 under selection pressure using doxorubicin from 10 nM to
1 µM concentration (Kars et al., 2006). Cell lines were maintained in
RPMI-1640 medium (LONZA) supplemented with 10% FBS, 2 mM
glutamine and penicillin-streptomycin solution at 37 °C, 5% CO2 and
95% humidity. MCF-7/KCR cells were cultured in media with 1 µM
doxorubicin for 1 week then in culture medium without doxorubicin for
1 week to maintain the drug-resistant phenotype. Before experiments,
MCF-7/KCR cells were grown in a doxorubicin-free medium.
2.3. Rhodamine 123 accumulation assay
MCF-7/KCR cells in 2 × 106 cells/well density were treated with
either 20 µM of compound 10b, 10c, 10d, 10f, 10g or 11b, 11c, 11d,
11f, 11g for 24 h or with verapamil in 40 µM concentration for 2 h.
Then cells were washed and re-suspended in serum-free RPMI-1640
medium containing 10 µM of Rhodamine 123 (RH123, Sigma-Aldrich).
Following 2 h incubation, cells were washed and RH123 fluorescence of
at least 10,000 cells/sample was measured by flow cytometry using
FACSCalibur™ platform. Data were analyzed by FlowJo V10 software.
Results were obtained from three independent experiments.
2.4. Immunoblotting
MCF-7/KCR cells (2 × 106cells/well) were treated with 20 µM 10 g
for 24 h. Then cell extracts were prepared using RIPA lysis buffer
(50 mM Tris (pH:7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and
1xProtease Inhibitor Cocktail), centrifuged at 13,000 rpm then super-
natants were collected. The protein concentration of the supernatants
was assessed by the Bradford method. 25 µg protein from the lysates
were resolved on 10% SDS-PAGE and transferred to nitrocellulose
membrane (Amersham). Membranes were blocked with 5% non-fat dry
milk in TBST (20 mM Tris, 150 mM NaCl and 0.05% Tween20) and
incubated overnight with primary MDR1 antibody (Santa Cruz sc-
55,510, used in 1:500 dilution), Bip (CST #3177T, used in 1:1000 di-
lution) and CHOP (CST #2895T, used in 1:1000 dilution) diluted in
TBST containing 1% non-fat dry milk, then with HRP-conjugated sec-
ondary antibody (DAKO). Equal loading was verified by detecting tu-
bulin, using an anti-tubulin primary antibody (eBioscience
14–4502–82, used in 1:1000 dilution) and HRP-conjugated secondary
antibody (DAKO). Membranes were developed with ECL reagent
(Millipore) and visualized by C-DiGit Blot Scanner (LI-COR). The pre-
sented images are representative blots from three individual experi-
ments.
2.5. Cell viability assay
Cells were seeded at 104/well density in 96-well plates. On the
following day, cells were treated with either 20 µM of compound 10g or
11g for 24 h or with verapamil in 40 µM concentration for 2 h. To
detect the sensitizing capability of compound 10g on multidrug-re-
sistant MCF-7/KCR cells to doxorubicin-induced toxicity, cells were
treated with 20 µM of compound 10g in combination with doxorubicin
in 10; 20; 40; 50 and 60 µM concentration. Following treatments cells
were washed and incubated with RPMI-1640 medium containing
0.5 mg/mL MTT reagent (Sigma-Aldrich). Formazan crystals were so-
lubilized in DMSO and absorbance was measured at 570 nm using a
Synergy HTX microplate reader (BIOTEK®). Measurements were re-
peated three times using 4 independent biological replicates.
Absorbance values of the untreated control samples were considered as
100% viability.
2.6. Apoptosis detection
Cells were seeded at 2 × 106 cells/well density in 6-well plates. On
the following day, cells were treated either with compound 10g or 11g
in 20 µM concentration or with doxorubicin (5 µM) for 24 h.
Combinational treatments using doxorubicin (5 µM) + verapamil
(4 µM) and doxorubicin (5 µM) + 10g (20 µM) as well as doxorubicin
(5 µM) + 11g (20 µM) were also performed. Cells were collected and
stained with AnnexinV-FITC/propidium iodide (PI) (Life Technologies)
according to the manufacturer's recommendation. Since fluorescent
properties of PI are similar to doxorubicin, we did not show PI filters in
the dot plots during analysis. Fluorescence intensities of at least 10,000
cells/sample were measured by FACSCalibur™ and data were analyzed
by FlowJo V10 software. Fluorescence of Annexin V-FITC and forward
scatter (FSC) were represented. Experiments were repeated three times
using at least three replicates.
2.7. Molecular docking assay
Homology model of the human MDR1 was obtained from the
SWISS-MODEL Repository (P08183) (Bienert et al., 2016). The three-
dimensional structure of 10g and 11g were built manually and energy
minimized using Chem3D Pro-ver 12.0. Molecular dockings were per-
formed with AutoDock ver. 4.2.6 (Morris et al., 2010). To cover the
putative ATP binding site of the receptor the grid volume was set up to
80 × 80 × 80 Å with 0.375 Å spacing and centered to the nucleotide-
binding domain 2. Rotatable bonds of 10g and 11g as well as receptor
amino acid side chains in contact with ATP were kept flexible
(Kadioglu et al., 2016; Mares-Sámano et al., 2009b). Blind docking was
carried out using the Lamarckian Genetic Algorithm, and 1000 dock-
ings were done. The resultant docked complexes were ranked according
to the corresponding binding free energies and inspected with Auto-
Dock Tools ver. 1.5.6 graphical interface. The lowest energy complex in
which 10g and 11g formed interactions with amino acids in the puta-
tive ATP binding site was selected and images were generated using
Pymol ver. 2.3.4 (PyMOL Molecular Graphics System, Schrödinger,
LLC.).
2.8. PharmMapper target prediction
PharmMapper is a web server that predicts therapeutic drug targets
for small molecules provided as query. 2D structures of 10g and 11g
were drawn using PubChem sketcher (“PubChem Sketcher V2.4,”). The
downloaded structures were given as an input for PharmMapper
available at http://www.lilab-ecust.cn/pharmmapper/. For human
targets parametric value was set to 2241, maximum number of matched
targets was set to 100 and all other parameters were set to default
values.
2.9. JC-1 staining
To measure changes in the mitochondrial membrane potential after
treatments, JC-1 staining was performed. Cells were seeded onto cov-
erslips placed into 24-well plates (105 cells/well). On the following day,
cells were treated with compound 10g or 11g in 20 µM concentration
or with carbachol in 500 µM concentration for 24 h. Carbachol was
used as a positive control, as it induces mitochondrial damage by
raising cytoplasmic calcium levels. Since JC-1 is a MDR1 substrate,
therefore, before JC-1 loading, 40 µM of verapamil was added to the
samples for 1 h. Then cells were washed and incubated with RPMI-1640
medium containing 10 µg/mL JC-1 (Life Technologies) for 15 min.
Coverslips were inversely mounted in Fluoromount™ (ThermoFisher)
on glass slides and JC-1 fluorescence was visualized by OLYMPUS BX51
microscope equipped with an Olympus DP70 camera using the same
exposition time for all samples. Image analysis was performed by
ImageJ software. We have to note that pretreatment of each sample
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with verapamil was required to improve intracellular retention of JC-1,
a MDR1 substrate, however, in those samples which were treated with
compound 10g inevitably more JC-1 was retained since these cells re-
ceived two MDR1 inhibitors (verapamil and compound 10g) (fig S1). As
a consequence, we could not apply the usual analysis and representa-
tion of JC-1 staining (aggregate/monomer ratio), but instead, the
average number of mitochondria/cell was counted in case of 100 cells
in each sample and expressed as a measure of mitochondrial damage.
Experiments were repeated three times using three independent bio-
logical replicates.
2.10. Reverse transcription and real-time PCR
Cells were seeded at 2 × 106 cells/well density in 6-well plates. On
the next day, cells were treated either with compound 10g or 11g in
20 µM concentration or with dithiothreitol (DTT, 2 mM) for 24 h. Total
cellular RNA was prepared using RNeasy®Mini Kit (QIAGEN) according
to the manufacturer's recommendation. 45 ng/µL RNA was reverse
transcribed (TaqMan® Reverse Transcription kit, Applied Biosystems).
PCR reactions were performed on PicoReal™ Real-time PCR (Thermo
Scientific) using SYBR Green qPCR Master Mix (Thermo Scientific) with
an input of 100 ng cDNA. Each primer (Table 1) was used at 200 nM
concentration. Relative transcript levels were determined by the ΔΔCt
analysis using GAPDH as the reference gene. Experiments were re-
peated three times using three biological replicates.
3. Results
3.1. Compound 10g inhibits MDR1 efflux activity in multidrug-resistant
breast cancer cells
Based on structure−cytotoxicity relationships verified previously
on numerous cancer cell lines (Baji et al., 2017), compounds 10b, 10c,
10d, 10f and 10g and their deacetylated counterparts 11b, 11c, 11d,
11f and 11g (chemical structures are shown in Fig 1 and supplementary
Fig S2) were selected from the compound library of synthetic hetero-
cyclic androstane derivatives for the present investigation (the original
compound numbers used in Baji et al. (Baji et al., 2017) were retained
for clarity and comparability). Multidrug-resistant MCF-7/KCR cells
were treated with these substances at 20 µM concentration for 24 h.
Drug-resistant phenotype of MCF-7/KCR cells was confirmed previously
by detecting significant MDR1 expression and high efflux activity in
these cells (Gopisetty et al., 2019) and the applied concentration of the
test compounds and the treatment time were established according to
preliminary experiments (unpublished results). Rhodamine 123 drug
efflux assay was performed to examine the potential inhibitory effects
of the test compounds on MDR1 activity. The fluorescent dye Rhoda-
mine 123 (RH123) is a substrate of MDR1, thus it can be readily ex-
pelled from drug-resistant cancer cells, whereas intracellular retention
of RH123 demonstrates inhibition of MDR1. As a positive control, cells
were treated with the known MDR1 inhibitor verapamil. The obtained
mean intracellular RH123 fluorescence values in MCF-7/KCR cells upon
treatments with the test compounds are represented in Table S1.
As expected, verapamil treatment resulted in the highest mean in-
tracellular RH123 fluorescence (Fig 2A and Table S1). Compared to the
fluorescence of cells receiving verapamil treatment (set as 100%) the
lowest intracellular fluorescence was found after treating MCF-7/KCR
cells with compounds 11b (4.6%), 11d (4.6%), 11f (6.4%), 11g (8.7%)
and 11c (9%), whereas the fluorescence of cells exposed to most
acetylated derivatives – apart from compound 10d (9.6%) - was sig-
nificantly higher i.e. 10f (24.6%), 10b (30.2%), 10c (42.6%) and 10g
(44.4%) (see Table S1). All the acetylated derivatives (10b, 10c, 10d,
10f, and 10g) manifested significant inhibitory potential on MDR1 ef-
flux activity, demonstrated by significantly higher intracellular RH123
fluorescence values, compared to the deacetylated counterparts (11b,
11c, 11d, 11f, and 11g) (Fig 2A, Fig S3 and Table S1), which clearly
indicates a strong structure−function relationship manifesting in
multidrug-resistant MCF-7/KCR cells. Among the tested compounds,
treatments with compound 10g resulted in the highest intracellular
RH123 accumulation, i.e. the strongest MDR1 inhibition (Fig 2A and
Table S1). Therefore, compound 10g was selected and applied in sub-
sequent experiments to uncover the precise mechanisms underlying the
inhibition of MDR1 efflux activity. To expose the possible differences in
molecular actions between the acetylated compound (10g) and its
deacetylated counterpart, compound 11g (the fluorescence intensity of
cells treated with 11g was only 8.7% compared to the fluorescence of
positive control) was also included in successive investigations. First, it
was validated that the concentration of 20 µM of compounds 10g and
11g - applied in the RH123 efflux assay - would not cause significant
cytotoxicity on MCF-7/KCR cells. For this, MTT assays were performed
after incubating the cells for 24 h with compounds 10g and 11g. Results
show that compared to untreated control the viable percentage of MCF-
7/KCR cells treated with 20 µM of 10g or 11g was 77.8 ± 22.8 and
97.5 ± 19.3, respectively. This indicates that neither of these two
compounds is able to induce serious cytotoxicity of drug resistant cells
at 20 µM concentration (Fig 2B).
DHT is a parent compound of the selected synthesized derivatives,
including 10g and 11g. To examine the possibility of the involvement
of hormonal effects exhibited by 10g (or by 11g) underlying MDR1
inhibition, DHT was tested for its inhibitory activity on MDR1-mediated
efflux in multidrug-resistant breast cancer cells. To achieve this, MCF-
7/KCR cells were treated with 20 µM DHT for 24 h then Rhodamine 123
assay was performed. Our results indicate that DHT treatment does not
lead to the inhibition of MDR1 activity (Fig 2C).
3.2. 10g treatment sensitizes multidrug-resistant breast cancer cells to
doxorubicin-induced killing
As the inhibition of MDR1 efflux leads to the intracellular retention
of chemotherapy drugs, it prolongs the time for the drug to exert its
anticancer activity within cancer cells, thus it improves the therapeutic
efficacy. Therefore, treatment with 10g, a MDR1 inhibitor, might sen-
sitize multidrug-resistant MCF-7/KCR cells to doxorubicin-induced cy-
totoxicity. To test this hypothesis, MCF-7/KCR cells were treated with
20 µM of 10g and with doxorubicin in 10, 20, 40, 50 and 60 µM con-
centrations for 24 h and compared the results with those obtained on
cells receiving only doxorubicin treatment at identical concentrations
as indicated above. We observed that treatment with 10g significantly
augmented the cytotoxicity provoked by doxorubicin in MCF-7/KCR
cells (Fig 3A). The IC50 values calculated from viability curves were
55.96±0.1 µM for doxorubicin and 35.26± 0.1 µM for 10g+doxor-
ubicin treatments, respectively (Fig S4). Next, we wanted to check
Table 1
Sequence of primers used in qPCR experiments.
Primer Forward Reverse
BIP 5′-TGTTCAACCAATTATCAGCAAACTC-3′ 5′-TTCTGCTGTATCCTCTTCACCAGT-3′
CHOP 5′-GGAGCATCAGTCCCCCACTT-3′ 5′-TGTGGGATTGAGGGTCACATC-3′
MDR1 5′-CTGTGATTGCATTTGGAGGA-3′ 5′-CCAGAAGGCCAGAGCATAAG-3′
GAPDH 5′-TGCACCACCAACTGCTTAGC-3′ 5′-GGCATGGACTGTGGTCATGAG-3′
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whether the improved toxic effects of doxorubicin in the presence of
compound 10 g are the result of enhanced apoptosis induction. MCF-7/
KCR cells were again treated with either 20 µM of 10 g or 5 µM dox-
orubicin or with the combination of 20 µM 10 g and 5 µM doxorubicin
for 24 h. Cells receiving only DMSO were considered as negative control
and those treated with 4 µM verapamil for 24 h were set as positive
control. The percentage of apoptotic cells (Q2+Q3) was 0.97% in
control samples, and it was 0.59% in doxorubicin-treated samples.
When cells were exposed to compound 10 g 1.86% of cells, by
doxorubicin+verapamil-treated cells 26.55%, and finally, 43.22% of
10 g+doxorubicin-exposed cells were undergoing apoptosis (Fig 3B). In
line with the viability results, Annexin V/PI apoptosis assay clearly
showed that treatments with compound 10 g+doxorubicin resulted in a
significantly higher number of apoptotic cells compared to cells re-
ceiving only doxorubicin treatment (Fig 3B). Surprisingly, the drug
sensitizing effect of 10 g seems to be stronger than that of verapamil, a
well-known MDR1 inhibitor. As expected, treatments with 20 µM of
11 g alone or in combination with 5 µM doxorubicin did not influence
Fig. 1. Chemical structures of DHT-derived A-ring-fused pyrimidinones 10g and 11g differing in their C-17 functionality.
Fig. 2. Compound 10g inhibits MDR1 efflux activity. A. MCF-7/KCR cells treated with 10g retain more intracellular Rhodamine 123, indicating inhibition of
MDR1 efflux activity, whereas, treatment with 11g did not influence the intracellular Rhodamine 123 levels compared to untreated control. B. MCF-7/KCR cells
treated with 20 µM of either 10g or 11g for 24 h manifest no significant cytotoxicity compared to untreated control cells. C. DHT treatment did not inhibit MDR1
efflux activity in MCF-7/KCR cells.
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MCF-7/KCR sensitivity to doxorubicin-induced apoptosis (Fig S5).
These results verify the MDR1 inhibiting feature of molecule 10 g and
indicate that in fact, there is a link between MDR1 inhibition and im-
proved doxorubicin sensitivity upon 10 g treatment.
3.3. In silico approaches predicted different binding targets of 10g and 11g
but similar binding to MDR1
Molecular docking study was carried out to predict if compound
10g or 11g is able to establish interactions with MDR1. In the lowest
energy complex, wherein ligands were bound to the nucleotide-binding
domain 2 of MDR1 (Fig 4A), the predicted binding free energy was
−6,53 kcal/mol for 10g, and −5.20 kcal/mol for 11g, respectively.
The acetoxy group of 10g formed a hydrogen bond with Tyr1044 while
the methyl group on the phenyl ring was predicted to interact with the
side chain of Arg1047. The pyrimidine ring attached with Arg262 and
Asp805 side chains, while Cys1074 was connected to the terminal cy-
clopentane ring (Fig 4B). Similar binding pose was revealed in case of
the deacetylated counterpart. The acetoxy substituting hydroxyl group
faced to Tyr1044 and Arg1047 residues, respectively. The main difference
Fig. 3. Treatment of multidrug-resistant MCF-7/KCR cells with 10g sensitizes them to doxorubicin-induced apoptosis. A. Combinational treatment using
doxorubicin in different concentrations and compound 10g significantly increased cytotoxicity of MCF-7/KCR cells, assessed by MTT assay. B. Combinational
treatment of doxorubicin and 10g significantly increased the percentage of Annexin V-positive (Q2+Q3) apoptotic cells compared to MCF-7/KCR cells receiving
doxorubicin or compound 10g alone.
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in the formed interactions of 11g that the methyl group on the phenyl
ring formed interaction with the side chain of Glu686. Additionally, the
sterane ring interacted with Asp805 and Pro807, respectively (Fig 4B).
Since in docking studies we did not see significant differences in pre-
dicted binding properties of 10g and 11g to MDR1, we proceeded for
PharmMapper analysis to find possible drug targets of 10g and 11g
(Wang et al., 2017, 2016). Unlike docking studies which rely on simple
free energy based fit scores, PharmMapper encompasses computational
tools that use ligand-pharmacophore fit scores. Thereby, predicts in si-
lico druggable targets of a query compound from annotated pharma-
cophore model database through reversed pharmacophore matching
thus improves prediction reliability. Among the top 10 potential pro-
teins predicted to be druggable targets of 10g and 11g in humans,
(Table 2) carbonic anhydrase 2, caspase 3, cholinesterase and peptidyl-
prolyl cis-trans isomerase were identified as typical 10g targets,
whereas caspase 7, PTP1B, KIF11 and aldo-keto reductase C3 were
found as potential 11g targets. However, here it has to be emphasized
that both molecular docking studies and PharmMapper analysis are in
silico tools to predict with fair confidence the molecular targets of a
given compound, but are not by themselves sufficient to either support
the supposed molecular mechanism or accurately prove the exact real-
life targets of the compounds.
3.4. Treatment with 10g does not influence either transcriptionally or
translationally the expression of MDR1 gene
After we did not detect significant difference in the predicted
binding properties of 10g and 11g to MDR1, although the MDR1-in-
hibiting property of compound 10g but not of 11g was identified, we
aimed to delineate the possible molecular mechanism/s behind the
10g-induced cellular phenomena. Inhibition of MDR1 expression either
transcriptionally and (or) translationally upon 10g treatment can be a
possible reason for the modulation of MDR1 efflux activity. It was also
previously suggested that proto-oncogenes CYCD and c-MYC are able to
regulate MDR1 expression (He et al., 2000; Wang et al., 2012). There-
fore, relative mRNA levels of MDR1, CYCD and c-MYC in MCF-7/KCR
cells exposed to 20 µM of 10g for 24 h were examined by quantitative
real-time PCR. Our results indicate that treatments with 10g did not
change the transcript levels of either MDR1, CYCD or c-MYC suggesting
that compound 10g does not influence the mRNA expression of MDR1
(Fig 5A). In a control experiment, the effect of compound 11g on the
expression levels of these genes was also investigated and no changes
were observed compared to untreated control cells (Fig S6). Then we
analyzed MDR1 protein levels of 10g-exposed multidrug-resistant cells.
Western blots revealed no difference in MDR1 protein expression be-
tween control and 10g-treated cells (Fig 5B). Our results imply that
compound 10g is not triggering the transcriptional and translational
activity of MDR1 gene, therefore the observed inhibition of MDR1-re-
lated efflux activity upon 10g treatment is not associated with the
regulation of its expression.
3.5. Treatments with 11g but not with 10g induce mitochondrial damage
MDR1 efflux is an energy-dependent process, therefore, cellular
energy status can have a direct impact on MDR1 activity. Hence, we
hypothesized that if compound 10g damages mitochondria this would
attenuate the ATP-driven MDR1-mediated membrane transport. To test
this hypothesis, MCF-7/KCR cells were treated with 20 µM of 10g, and
for comparison also with compound 11g for 24 h. As a positive control,
cells were exposed to 500 µM carbachol for 24 h, since carbachol in-
duces mitochondrial damage by raising cytoplasmic calcium levels.
After the treatments, JC-1 staining was performed and the stained cells
were observed under fluorescence microscope. The average number of
mitochondria/cell was counted and expressed as a measure of
Fig. 4. In silico molecular docking
predicted the binding of 10g and 11g
to MDR1. A. Lowest energy docked
complexes of 10g and MDR1. B.
Predicted interactions of 10g and 11g
with the nucleotide-binding domain 2
of MDR1. 10g is yellow while 11g is
magenta coloured. Receptor amino
acid side chains with interactions with
the ligands are labeled and pink-co-
loured.
Table 2
PharmMapper generated top ten druggable targets of 10g and 11g.
Rank 10g targets 11g targets
1 Serine/threonine-protein kinase
Pim-1
Integrin alpha-L
2 Carbonic anhydrase 2 Serine/threonine-protein kinase
Pim-1
3 Integrin alpha-L Aldose reductase
4 Aldo-keto reductase C2 Aldo-keto reductase C2
5 Bone morphogenetic protein 2 Bone morphogenetic protein 2
6 Caspase-3 Caspase-7
7 Aldose reductase PTP1B
8 Cholinesterase Mitogen-activated protein kinase 1
9 Peptidyl-prolyl cis-trans isomerase Kinesin-like protein KIF11
10 Mitogen-activated protein kinase 1 Aldo-keto reductase C3
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mitochondrial damage, where lower values indicate significant damage
to this organelle. Results indicate that 10g treatment did not induce
mitochondrial damage, whereas compound 11g triggered significant
reduction in the number of functional mitochondria (Fig 6). If the un-
derlying cause of the observed inhibition of MDR1 efflux activity was
the damage to mitochondria, then compound 11g should have mani-
fested a more efficient efflux inhibition compared to 10g. Since this was
not the case, our results rule out the direct link between 10g-induced
MDR1 inhibition and mitochondrial damage.
3.6. Compound 10g induces endoplasmic reticulum stress in multidrug-
resistant cancer cells
Cellular distribution of MDR1 can be disturbed due to endoplasmic
reticulum (ER) stress (Gopisetty et al., 2019). Moreover, our in silico
experiments revealed that one among the predicted druggable targets of
compound 10g is peptidyl-prolyl cis-trans isomerase (Table 2), which
protein is strongly associated with protein folding in the ER and its
inhibition leads to ER stress (Kim et al., 2008). Therefore, we supposed
that if compound 10g induces ER stress in multidrug-resistant MCF-7/
Fig. 5. 10g treatment does not affect MDR1 expression in MCF-7/KCR cells. A. Treatments with 10g do not induce significant changes in the transcript levels of
MDR1, CYCD and c-MYC. B. 10g treatment does not affect MDR1 protein levels. Values represent mean±SD calculated from three independent experiments.
Fig. 6. 10g induced MDR1 inhibition in MCF-7/KCR cells is not the result of mitochondrial damage. In contrast to exposures of MCF-7/KCR to 10g, where no
mitochondrial damage is observed, treatment with 11g induces significant loss of functional mitochondria (yellow colored spots in the fluorescent images). Carbachol
was used as positive control. Values represent average number of mitochondria counted from at least 25 cells (****P < 0.0001, Fisher's LSD test).
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KCR cells then this could explain the attenuated MDR1 efflux activity
upon treatments with 10g. To address this issue, MCF-7/KCR cells were
treated with 20 µM of 10g, or for comparison with 11g for 24 h and
transcriptional and translational activation of ER stress response genes
BIP and CHOP were measured using quantitative real-time PCR and
western blot respectively. Cells exposed to 4 mM of dithiothreitol (DTT)
for 24 h served as positive control for the induction of ER stress. Our
results revealed that 10g but not 11g induces significant increase in the
expression levels of the ER stress response genes BIP and CHOP com-
pared to untreated control (Fig 7A, B), which implies the involvement
of this cellular stress condition in the complex molecular mechanism
behind MDR1 inhibition.
4. Discussion
The success of cancer chemotherapy is largely limited by inherent or
attained multidrug resistance of cancer cells. Often, upon exposure to
therapeutic drugs, cancer cells undergo an evolution by rewiring their
molecular mechanisms resulting in cancer cell phenotypes which are
capable to evade the toxic effects of therapeutic drugs. Among the
various mechanisms involved in this process, the upregulation of MDR1
is predominant since it ensures cancer cell resistance to many structu-
rally and functionally dissimilar drugs. Fueled by ATP hydrolysis,
MDR1 pumps drugs out of cancer cells keeping the intracellular amount
of these agents below the required concentration to elicit cytotoxicity.
Therefore, inhibition of MDR1 has always been regarded as a promising
approach to improve cancer chemotherapy also in clinical settings.
Despite the fact that numerous MDR1 inhibitors were tested and have
failed in clinical trials due to questionable safety and thus were dis-
missed for further therapeutic applications, the quest for potent MDR1
modulators is still on (Chung et al., 2016).
In the present work we examined a series of pyrimidinones fused to
the A-ring of DHT or DHT-acetate (Baji et al., 2017) and compared their
MDR1 inhibiting properties in MCF-7/KCR cells that overexpress
MDR1. Here we show a remarkable structure-related discriminative
behavior manifested by these androstane-derivatives on MDR1 activity,
since all the 17-acetylated derivatives 10b, 10c, 10d, 10f, 10g ex-
hibited a marked MDR1 inhibitory potential in contrast to their 17-OH
pairs 11b, 11c, 11d, 11f, 11g (Fig S3, Fig 2A). As compound 10g
showed the highest capacity in hindering the MDR1 efflux activity
(table S1) from all the tested derivatives 10g and its deacetylated pair
11g were selected for subsequent experiments to unravel the possible
mechanisms behind the 10g-induced reduction in MDR1 function.
Based on previous cytotoxicity tests 10g or 11g were applied in 20 µM
concentration in further experiments as this concentration did not cause
any cytotoxicity on the examined cell lines (Fig 2B). The fact that DHT,
a parent compound with a similar structural platform, did not show
MDR1 inhibitory activity (Fig 2C) indicates a modification-dependent
gain-of-function of the acetoxy group carrying by the A-ring fused ar-
ylpyrimidinone-androstanes.
The drug resistance displayed by MCF-7/KCR signifies that such
cancer cells can evade the toxic effects of unusually high concentrations
of doxorubicin (Gopisetty et al., 2019). Treatment with 10g improved
cytotoxicity of doxorubicin (Fig 3A) indicated by decreased IC50 values
for this drug (Fig S4) in cells co-treated with 10g, compared to cells
treated with doxorubicin alone. Furthermore, we proved that 10g
treatment sensitizes drug-resistant MCF-7/KCR cells to doxorubicin-
induced apoptosis (Fig 3B). Surprisingly, the doxorubicin-sensitizing
effect of 10g exceeded that of the well-known, first generation MDR1
inhibitor and our positive control verapamil (Fig 3B). Molecular
docking for 10g and 11g performed to predict their binding to MDR1
and other druggable targets, revealed no significant differences in their
binding properties with MDR1 (Fig 4A, B). Nevertheless, other in silico
approaches (such as PharmMapper) revealed different predicted
binding targets for these molecules, among them peptidyl-prolyl cis-
trans isomerase as a potential target of compound 10g, which is a
protein involved in physiological ER functions (table 2).
Down-regulation of MDR1 expression would undoubtedly impact
the quantity of drugs expelled by MDR1 efflux; therefore, we analyzed
the transcript and the protein levels of MDR1 as well as the relative
mRNA amount of well-known MDR1 gene expression regulators c-MYC
and CYCD following treatment of MCF-7/KCR cells with compound
Fig. 7. 10g treatment induces endoplasmic re-
ticulum stress in MCF-7/KCR cells. A. Treatment
with compound 10g leads to elevated relative mRNA
(A) and protein (B) levels of the important ER stress
response genes BIP and CHOP, as representative blots
indicate. Values represent mean± SD calculated from
three independent experiments. (****P < 0.0001,
Fisher's LSD test).
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10g. The results imply that these two latter genes were not tran-
scriptionally elevated (Fig 5A) upon 10g treatment and obeying these
data MDR1 was also not down- or upregulated either transcriptionally
(Fig 5A) or translationally (Fig 5B).
Drug efflux through MDR1 is an energy-dependent process, which
consumes energy from ATP hydrolysis; therefore, mitochondria - the
major generators of cellular ATP - are indirectly linked to ABC trans-
porter activity. Mitochondrial damage can lead to a reduced MDR1
efflux due to insufficient cellular ATP. A direct correlation between
MDR1 inhibitory activity and cellular ATP diminishing capacity was
verified in a recent report on the novel compound RY10–4 (Xue et al.,
2014). To test the possibility of mitochondrial dysfunction, MCF-7/KCR
cells were treated with either compound 10g or 11g or as a positive
control with carbachol, and JC-1 staining was performed to measure
mitochondrial health. We observed that treatment with molecule 11g
induced significant damage to mitochondria (Fig 6), whereas com-
pound 10g did not induce similar mitochondrial impairment. These
findings rule out the possibility of mitochondrial damage being the
underlying factor of the observed MDR1 inhibition following treatment
with 10g.
Endoplasmic reticulum is the major site of protein homeostasis.
Perturbations in its function lead to ER stress and deregulation of the
protein folding machinery. Since MDR1 is a glycoprotein, it requires
proper handling by the ER to be capable to attain its functional con-
formation before reaching the plasma membrane. Endoplasmic re-
ticulum stress perturbs the proper folding of this transport protein,
which leads to a decreased number of functional MDR1 in the plasma
membrane resulting in diminished efflux activity. Since a direct con-
nection between endoplasmic reticulum stress and inhibition of MDR1
activity has already been demonstrated (Gopisetty et al., 2019),
therefore we hypothesized that compound 10g might induce en-
doplasmic reticulum stress as well, ultimately precipitating to a de-
creased efflux function. To test this hypothesis, the relative changes in
the transcript and protein levels of ER stress markers BIP and CHOP
were assessed in MCF-7/KCR cells treated either with compound 10g or
11g or with the ER stress inducer compound DTT. Our results strongly
indicate that 10g treatment induces significant endoplasmic reticulum
stress, as both the mRNA and the protein levels of CHOP and BIP were
increased upon 10g exposures (Fig 7). We did not observe significant
mRNA expression of these ER stress markers in multidrug-resistant
cancer cells treated with molecule 11g (Fig 7); nevertheless, the protein
expression of CHOP was somewhat elevated following 11g treatments
(Fig 7B).
CHOP is activated during ER stress; however, ER stress is not the
only source of CHOP activation. Cellular stresses other than ER stress
through p38 MAPK also activate CHOP (Sano and Reed, 2013). Absence
of transcriptional and translational elevation of BIP suggests that 11g-
induced CHOP activation might not be the result of ER stress. Moreover,
stress induced CHOP activation is mostly post- transcriptional (Bi et al.,
2005), which explains the possibility for observed elevation in protein
but not in mRNA levels of CHOP in our results (Fig 7A, B). These
findings demonstrate the reasonable implication of this cellular stress
condition in the complex molecular mechanism leading to MDR1 in-
hibition. However, further studies are required to ascertain this con-
nection.
The present study proved that novel A-ring-fused arylpyrimidine
androstane derivatives exhibit MDR1-inhibiting potential in multidrug-
resistant adenocarcinoma cells and we unraveled some of the possible
molecular events underlying this feature. Furthermore, we also proved
that the MDR1 inhibitory activity of these A-ring-fused arylpyr-
imidinones is strongly dependent on their acetylation status. With
further studies, our present work can open a structural platform for the
design and synthesis of new generation MDR1 inhibitors that can at-
tenuate drug resistance and sensitize resistant cancer cells to clinically
applied chemotherapy drugs. Apart from oncotherapeutic approaches,
these molecules could also be utilized in the treatment of other
pathological conditions like epilepsy (Summers et al., 2004).
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